Skip to content
Quinaglute, Nuedexta(quinidine)
Cardioquin, Cin-quin, Duraquin, Nuedexta, Quinact, Quinaglute, Quinalan, Quinatime, Quinidex, Quinora (quinidine) is a small molecule pharmaceutical. Quinidine was first approved as Quinaglute on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. It has been approved in Europe to treat neurobehavioral manifestations. It is known to target potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 5, equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily H member 5, potassium voltage-gated channel subfamily H member 1, potassium channel subfamily K member 5, potassium channel subfamily T member 1, potassium channel subfamily T member 2, potassium channel subfamily K member 18, potassium channel subfamily K member 6, potassium channel subfamily K member 16, potassium channel subfamily K member 10, potassium voltage-gated channel subfamily A member 4, sodium channel protein type 5 subunit alpha, potassium voltage-gated channel subfamily D member 2, potassium channel subfamily U member 1, and cytochrome P450 2D6.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
behavior and behavior mechanismsD001520
Trade Name
FDA
EMA
Combinations
Nuedexta (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dextromethorphan hydrobromide
+
Quinidine sulfate
Tradename
Company
Number
Date
Products
NUEDEXTAAvanir PharmaceuticalsN-021879 RX2010-10-29
1 products, RLD, RS
Quinidine gluconate
Tradename
Company
Number
Date
Products
QUINAGLUTEBayerN-016647 DISCN1982-01-01
1 products, RLD
QUINIDINE GLUCONATEEli LillyN-007529 DISCN1989-02-10
1 products, RLD
DURAQUINWarner ChilcottN-017917 DISCN1982-01-01
1 products
Hide discontinued
Quinidine polygalacturonate
Tradename
Company
Number
Date
Products
CARDIOQUINPharmaceutical Research Associates IncN-011642 DISCN1982-01-01
1 products
Hide discontinued
Quinidine sulfate
Tradename
Company
Number
Date
Products
QUINIDEXWYETH PHARMS INCN-012796 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nuedextaNew Drug Application2022-11-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiac arrhythmiasEFO_0004269D001145I49.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dextromethorphan Hydrobromide / Quinidine Sulfate, Nuedexta, Avanir Pharms
76592822026-08-13U-1093
82274842023-07-17U-1093
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BA: Antiarrhythmics, class ia
— C01BA01: Quinidine
— C01BA51: Quinidine, combinations excl. psycholeptics
— C01BA71: Quinidine, combinations with psycholeptics
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameQUINIDINE
INN—
Description
Quinidine is a cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. It has a role as an alpha-adrenergic antagonist, an antimalarial, an anti-arrhythmia drug, a sodium channel blocker, a muscarinic antagonist, a potassium channel blocker, a P450 inhibitor, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor and a drug allergen. It derives from a hydride of a cinchonan.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
Identifiers
PDB4WNU
CAS-ID56-54-2
RxCUI9068
ChEMBL IDCHEMBL1294
ChEBI ID28593
PubChem CID441074
DrugBankDB00908
UNII ID—
Target
Agency Approved
No data
Alternate
KCNA7
KCNA7
KCNA5
KCNA5
SLC29A4
SLC29A4
KCNH5
KCNH5
KCNH1
KCNH1
KCNK5
KCNK5
KCNT1
KCNT1
KCNT2
KCNT2
KCNK18
KCNK18
KCNK6
KCNK6
KCNK16
KCNK16
KCNK10
KCNK10
KCNA4
KCNA4
SCN5A
SCN5A
KCND2
KCND2
KCNU1
KCNU1
CYP2D6
CYP2D6
Organism
Homo sapiens
Gene name
KCNA7
Gene synonyms
NCBI Gene ID
3743
Protein name
potassium voltage-gated channel subfamily A member 7
Protein synonyms
potassium channel, voltage gated shaker related subfamily A, member 7, potassium voltage-gated channel, shaker-related subfamily, member 7, voltage-dependent potassium channel Kv1.7, voltage-gated potassium channel KCNA7, Voltage-gated potassium channel subunit Kv1.7
Uniprot ID
Q9BYS4
Mouse ortholog
Kcna7 (16495)
potassium voltage-gated channel subfamily A member 7 (Q17ST2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 12,932 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details